Výsledky vyhledávání - "Julie Satterwhite"

Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis

Autor: Subhashis Banerjee, Gregory S Cameron, Julie Satterwhite, Siak‐Leng Choi, Lai‐San Tham, Cheng‐Cai Tang

Publikováno v: The Journal of Clinical Pharmacology. 54:1117-1124

Ixekizumab (LY2439821), a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds and neutralizes interleukin (IL) 17A has demonstrated efficacy in the treatment of psoriasis. A population pharmacokinetics-pharmacodyna

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6846bbaf1c4d84b4fe726adf7228b5ab
https://doi.org/10.1002/jcph.312

Zobrazit plný text záznamu

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis

Autor: Michael Heathman, Harald Dobnig, Julie Satterwhite, Paul D. Miller, Emmett V. Glass, Fernando Marin

Publikováno v: Calcified Tissue International

Teriparatide (rhPTH[1–34]) affects calcium metabolism in a pattern consistent with the known actions of endogenous parathyroid hormone (PTH). This report describes the pharmacokinetics and resulting serum calcium response to teriparatide in postmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9268b8800790399e93249d8ce9f5563a
http://europepmc.org/articles/PMC2978887

Zobrazit plný text záznamu

Modulation of Blood Pressure by Central Melanocortinergic Pathways

Autor: Soren Brage, Elana Henning, John P. Mayer, Jerry R. Greenfield, Gregory S Cameron, Jeffrey W Miller, Teik Choon See, Stephen O'Rahilly, I. Sadaf Farooqi, Julia M. Keogh, David J. Lomas, Beatrice Astruc, Julie Satterwhite

Publikováno v: New England Journal of Medicine. 360:44-52

Weight gain and weight loss are associated with changes in blood pressure through unknown mechanisms. Central melanocortinergic signaling is implicated in the control of energy balance and blood pressure in rodents, but there is no information regard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f1340a42cdcbb1f2b44d948fc59b1e
https://doi.org/10.1056/nejmoa0803085

Zobrazit plný text záznamu

Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers

Autor: Robert A. Dean, Eric Siemers, Martin R. Farlow, Michael H. Skinner, Patrick J. C. May, Daniel K. Ness, Celedon Gonzales, Julie Satterwhite

Publikováno v: Clinical Neuropharmacology. 28:126-132

Amyloid beta (Abeta) may play a central role in the pathogenesis of Alzheimer disease. A functional gamma-secretase inhibitor, LY450139, was developed that inhibits Abeta formation in whole cell assays, transgenic mice, and beagle dogs. The authors w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b1fa635f614e79820af34bd1ab6585
https://doi.org/10.1097/01.wnf.0000167360.27670.29

Zobrazit plný text záznamu

The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis

Autor: Robert Marcus, Ouhong Wang, Bruce H. Mitlak, Julie Satterwhite

Publikováno v: Journal of Bone and Mineral Research. 18:18-23

In a recent study of women with postmenopausal osteoporosis, treatment with teriparatide for a median of 19 months increased bone mineral density and decreased the risk of vertebral and nonvertebral fractures. Using the same cohort, the current study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6dd011c60f7eee8c67e72a2d45cc19
https://doi.org/10.1359/jbmr.2003.18.1.18

Zobrazit plný text záznamu

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

Autor: Mark C. Genovese, Stephen L. Myers, Olivier Bénichou, Melissa Veenhuizen, Julie Satterwhite, Eric Lee, Gregory D. Sides, Damon Disch, Pierre-Yves Berclaz

Publikováno v: Annals of the rheumatic diseases. 72(9)

To assess the dose-response relationship, efficacy and safety of tabalumab, a human monoclonal antibody that neutralises membrane-bound and soluble B-cell activating factor (BAFF), in patients with rheumatoid arthritis (RA) with inadequate response t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341d7517aa9889a20114ac8cf9ffe04b
https://pubmed.ncbi.nlm.nih.gov/23599435

Zobrazit plný text záznamu

Preclinical and Clinical Pharmacology of Efegatran (LY294468) : A Novel Antithrombin for the Treatment of Acute Coronary Syndromes

Autor: Charles V. Jackson, Eiry Roberts, Julie Satterwhite

Publikováno v: Clinical and Applied Thrombosis/Hemostasis. 2:258-267

Efegatran (LY294468), a tripeptide arginal in hibitor of the catalytic site of thrombin, is being devel oped as a parenteral anticoagulant for the treatment of acute coronary syndromes. Efegatran was studied in a canine model of coronary artery throm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d0297d514c180b0a42e09a50b04d8bb7
https://doi.org/10.1177/107602969600200406

Zobrazit plný text záznamu

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors

Autor: Stephen L. Myers, Mark C. Genovese, Olivier Bénichou, Roy Fleischmann, Maria Greenwald, Li Xie, Melissa Veenhuizen, Pierre-Yves Berclaz, Julie Satterwhite

Publikováno v: Annals of the rheumatic diseases. 72(9)

Objective To evaluate the efficacy and safety of tabalumab, a monoclonal antibody that neutralises membrane-bound and soluble B-cell activating factor (BAFF), in patients with active rheumatoid arthritis (RA) who showed inadequate response to tumour

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4a341b150c0467addbd53addf8c0264
https://pubmed.ncbi.nlm.nih.gov/23268367

Zobrazit plný text záznamu

Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity

Autor: Cynthia Darshini Jesudason, Christopher John Rito, James E. Baker, Aidas Kriauciunas, Minxia M. He, William G. Trankle, Robert D. Bryant, Frank C. Tinsley, Gregory A Gaich, Julie Satterwhite, Steven D. Kahl, Anthony J. Shuker, Libbey S. O’Farrell, Mary A. Peters, Fisher Jack Wayne, Mark L. Heiman

We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::799540a006049b90706c7577cf79b371
https://europepmc.org/articles/PMC4018109/

Zobrazit plný text záznamu

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

Autor: Julie Satterwhite, Derek M Misurski, Rachel B. Wagman, Peiqi Chen, E. Michael Lewiecki, Angelo A. Licata, Adrien Sipos

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 20(6)

UNLABELLED: The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied. Changes in five biochemical markers, obtai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c7924586170f84d7ecf6aca77071cc2
https://pubmed.ncbi.nlm.nih.gov/15883636

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání